Date: 2014-10-15
Type of information: Services contract
Compound: profiling of a lead oncology asset
Company: Horizon Discovery (UK) undisclosed top ten pharma company
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: services
Action mechanism:
Disease:
Details: * On October 15, 2014, Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, announced that its Horizon CombinatoRx division has been contracted by a top ten pharma company to profile a lead oncology asset.
Horizon will provide services to support proof-of-concept, monotherapy screening, and combination screening for the lead asset. Horizon CombinatoRx provides its partners access to the cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations. Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, Horizon CombinatoRx offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.
Financial terms: Under the terms of the agreement, Horizon CombinatoRx will be paid approximately $450,000 (GBP £276,000) for work to be completed within a six month period.
Latest news:
